Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical settings. Many individual studies as well as large projects like the Psychiatric Ratings using Intermediate Markers (PRISM) studies and the Psychiatric Biomarkers Network (PBN) have been looking at multiple biomarker types, and have begun to identify predictors of specific symptoms, or disease progression. Read More
Transthera Sciences Inc. is out-licensing one of its preclinical NLRP3 inhibitors to Neurocrine Biosciences Inc. under a collaboration agreement worth $881.5 million. Under deal terms, Nanjing, China-based Transthera will receive an undisclosed up-front payment and is eligible to receive research and development and sales-based milestone payments up to $881.5 million. Read More
Researchers from Sionna Therapeutics Inc. presented preclinical efficacy data on first-in-class NBD1 stabilizers and their use in combination with complementary modulators to correct cystic fibrosis transmembrane conductance receptor (CFTR) assembly. Read More
Leukogene Therapeutics Inc.’s lead product candidate LTI-214 (M2T-CD33) has been awarded orphan drug designation by the FDA for the treatment of acute myeloid leukemia (AML). Read More
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. Read More
Editor Annette Boyle discusses the challenges med-tech companies face in bringing innovation to market and how the industry can overcome them. Read More
Advanced gastric cancer continues to pose a significant medical challenge because of the scarcity of effective treatments and the frequent development of resistance to available drugs. Read More
Boehringer Ingelheim Pharma GmbH & Co KG and CDR-Life Inc. have entered into a new global licensing agreement to develop CDR-111 for autoimmune diseases. Read More
Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of Gensci-143, is in metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors. Read More
Prelude Therapeutics Inc. has outlined its plans to prioritize programs within its pipeline and announced an exclusive option agreement with Incyte Corp. Read More
Carbon Biosciences Inc. has presented data on a parvovirus-based vector that restores full-length cystic fibrosis transmembrane conductance regulator (CFTR) gene for treating cystic fibrosis. Read More
Glutathione transferase omega-1 (GSTO1-1) helps drive inflammatory disorders and cancers by activating the NLRP3 inflammasome and promoting production of pro-inflammatory interleukin-1b. Numerous small molecules have been generated to inhibit the enzyme, but none has progressed to clinical trials, mostly because of off-target activity or poor pharmacokinetics. Read More
Shanghai Apeiron Biotechnology Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) reported to be useful for the treatment of cancer. Read More
Nanjing Nuoyuan Medical Devices Co. Ltd. has synthesized heptamethine cyanine near infrared (NIR) dyes reported to be useful for diagnosis of cancer. Read More
Haisco Pharmaceutical Group Co. Ltd. has divulged cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of inflammatory, renal, psychiatric, cardiovascular, eye, respiratory and metabolic disorders, as well as cancer. Read More
